Cheryl Cohen - 02 Jul 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship: Director
Issuer ticker: IBRX
Reported as of: 02 Jul 2026
Net transaction value: -$1,246,941
SEC form: 4
Accepted by SEC: 06 Jul 2026, 20:26:22 UTC
Prior SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Philip LoScalzo, as Attorney-in-Fact

Key filing fact

Cheryl Cohen filed Form 4 for ImmunityBio, Inc. (IBRX) on 06 Jul 2026.

Key facts

This page summarizes Cheryl Cohen's Form 4 filing for ImmunityBio, Inc. (IBRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 20:26.

Change

Previous filing in this sequence was filed on 29 Jun 2026.
Current net transaction value: -$1,246,941.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001529371 Primary reporting owner

Cohen Cheryl

Relationship: Director
Address: C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
Signature: /s/ Philip LoScalzo, as Attorney-in-Fact
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IBRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +55,979
Change %: +28%
Price: $2.98^*
Shares after: 256,596
Date: 02 Jul 2026
Ownership: Direct

IBRX transaction

Common Stock

Sale

Transaction value: $1,246,941
Shares: -131,210
Change %: -51%
Price: $9.50
Shares after: 125,386
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBRX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -55,979
Change %: -33%
Price: $0.000000^*
Shares after: 111,958
Date: 02 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,979
Exercise price: $2.98

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.

Footnote F2

Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.